Identification of a regulatory allosteric site in Arid5a unveils a therapeutic axis for systemic inflammation.

Summary

This study identified a conserved allosteric site in Arid5a and developed two picolinamide-based inhibitors, NFP1 and NFP2. The inhibitors disrupted Arid5a binding to target RNA, reduced Il6 and other inflammatory mRNA stability, attenuated macrophage and Th17-cell inflammation, and improved survival and organ injury in a murine lipopolysaccharide-induced septic shock model.

Key Findings

• A conserved regulatory allosteric site was identified within the Arid5a ARID domain.
• NFP1 and NFP2 reduced Arid5a-dependent stabilization of Il6, Stat3, and OX40 mRNAs and attenuated inflammatory responses.
• Both inhibitors improved survival, clinical severity, and vital-organ injury in a murine lipopolysaccharide-induced septic shock model.

Clinical Implications

Arid5a allosteric inhibitors could eventually provide a host-directed therapy for excessive systemic inflammation and septic shock. However, pharmacokinetics, toxicity, infection-control effects, and efficacy in clinically relevant polymicrobial sepsis models must be established before human trials.

Limitations

• The evidence is preclinical and relies substantially on lipopolysaccharide-induced rather than polymicrobial sepsis models.
• Human pharmacology, toxicity, tissue distribution, and the effects of Arid5a inhibition on antimicrobial host defense were not established.

Future Directions

Future studies should evaluate the inhibitors in clinically relevant polymicrobial sepsis models, define dose-exposure relationships and safety margins, and determine whether selective Arid5a inhibition preserves pathogen clearance while reducing harmful inflammation.